34 completed, 3 unknown, 1 not yet recruiting. 38 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 38 | Completed 34, Unknown 3, Not yet recruiting 1 |
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Ticagrelor: new trials by email Literature Review of Ticagrelor trials Research Report on Ticagrelor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets - Healthy Volunteer | Phase 1 | Not yet recruiting | Advenchen Laboratories Nanjing Ltd. | 16 | 2026-03-02 | 2026-02-27 |
| Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination. A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.), A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.) - Healthy | Phase 1 | Completed | Laboratorios Silanes S.A. de C.V. | 24 | 2025-01-13 | 2026-03-02 |
| Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects Tiprogrel, Clopidogrel, Ticagrelor - Acute Coronary Syndrome, Ischemic Stroke | Phase 1 | Completed | Tianjin Institute of Pharmaceutical Research Co., Ltd | 14 | 2024-09-09 | 2025-01-06 |
| A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects YZJ-1139 tablets, Ticagrelor Tablets - Insomnia | Phase 1 | Completed | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | 27 | 2024-08-22 | 2026-06-30 |
| A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participants Rosuvastatin, Ticagrelor - Healthy Participants | Phase 1 | Completed | AstraZeneca | 28 | 2024-08-05 | 2025-04-18 |
| De-escalation of Ticagrelor in Post PPCI Ticagrelor 60mg - Ticagrelor | Phase 1 / Phase 2 | Unknown | Assiut University | 400 | 2023-06-01 | 2023-04-26 |
| KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug Placebo, Ticagrelor, Rosuvastatin - Pharmacokinetics | Phase 1 | Unknown | Helsinki University Central Hospital | 10 | 2022-05-11 | 2022-05-13 |
| Safety and Effectiveness of Ticagrelor in Patients Undergoing Carotid Stenting Ticagrelor, Clopidogrel, Carotid stenting - Carotid Stenosis | Phase 1 | Unknown | Assiut University | 26 | 2022-01-01 | 2021-03-23 |
| Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition Anplag (Ticagrelor 90 mg), Brilinta (Ticagrelor 90 mg) - Healthy Individuals | Phase 1 | Completed | University of Karachi | 30 | 2020-10-16 | 2022-09-08 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects AZD3366, Placebo, Ticagrelor - Cardiovascular Disease | Phase 1 | Completed | AstraZeneca | 103 | 2020-10-15 | 2023-12-18 |
| The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease Ticagrelor - Platelet Dysfunction Due to Drugs | Phase 1 / Phase 2 | Completed | The University of The West Indies | 25 | 2019-10-01 | 2020-05-21 |
| Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy Volunteers D578, CKD-357 - Acute Coronary Syndrome | Phase 1 | Completed | Chong Kun Dang Pharmaceutical | 31 | 2018-05-25 | 2018-09-19 |
| PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4) Ticagrelor - Sickle Cell Disease | Phase 1 | Completed | AstraZeneca | 21 | 2018-03-28 | 2021-05-10 |
| A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor Ticagrelor 90mg, Epinephrine, Metoprolol - Healthy Volunteers | Phase 1 | Completed | Vastra Gotaland Region | 10 | 2018-02-28 | 2018-05-11 |
| A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects ACT-246475, Clopidogrel, Prasugrel - Healthy | Phase 1 | Completed | Viatris Innovation GmbH | 77 | 2018-01-24 | 2025-07-03 |
| A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water - Sickle Cell Disease | Phase 1 | Completed | AstraZeneca | 44 | 2017-05-12 | 2017-08-02 |
| Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube - Bioavailability, Healthy Subjects | Phase 1 | Completed | AstraZeneca | 100 | 2015-06-01 | 2016-09-29 |
| Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water, Ticagrelor OD tablet (90 mg single dose) administered without water, Ticagrelor IR tablet (90 mg) administered with 150 mL of water - Bioequivalence, Healthy Japanese Subjects | Phase 1 | Completed | AstraZeneca | 51 | 2015-06-01 | 2017-01-11 |
| The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese Ticagrelor - Healthy | Phase 1 | Completed | Guangdong Provincial People's Hospital | 51 | 2015-05-20 | 2017-03-27 |
| Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis ticagrelor, Placebo - End Stage Renal Disease, Vascular Access Patency | Phase 1 / Phase 2 | Completed | University of Virginia | 54 | 2014-12-01 | 2022-06-08 |
Showing 20 of 38. Sign in to see all of them.
Acute Coronary Syndrome (5) · Anemia, Sickle Cell (2) · Ischemic Stroke (2) · Kidney Failure, Chronic (2) · Acute Lung Injury (1) · Atrial Fibrillation (1) · Cardiovascular Diseases (1) · Carotid Stenosis (1) · Chronic Limb-Threatening Ischemia (1) · Community-Acquired Pneumonia (1) · Coronary Artery Disease (1) · Gout (1) · Healthcare-Associated Pneumonia (1) · Heartburn (1) · Pneumonia (1)
AstraZeneca (17) · Assiut University (2) · Boehringer Ingelheim (2) · Advenchen Laboratories Nanjing Ltd. (1) · Asan Medical Center (1) · Chong Kun Dang Pharmaceutical (1) · Guangdong Provincial People's Hospital (1) · Helsinki University Central Hospital (1) · LG Life Sciences (1) · Laboratorios Silanes S.A. de C.V. (1) · Medical University of Vienna (1) · Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (1) · The University of The West Indies (1) · Tianjin Institute of Pharmaceutical Research Co., Ltd (1) · University of Karachi (1)
United States (11) · Germany (5) · China (4) · South Korea (3) · Sweden (3) · United Kingdom (3) · Austria (1) · Belgium (1) · Finland (1) · Italy (1) · Japan (1) · Kenya (1) · Lebanon (1) · Mexico (1) · Pakistan (1)
Kathleen Butler, MD (3) · Kelli Craven, MD (2) · Rainard Fuhr, Dr. med. (2) · Anders Jeppsson, MD,PhD,Prof (1) · Annelize Koch, Dr. (1) · David Han (1) · Glenn Carlson, MD (1) · Hidenori Komori, MD PHD (1) · Hyeong-Seok Lim, Professor (1) · Jay Horrow, MD (1) · Jay Horrow, PhD (1)
PMID 21960668, PMID 22168538, PMID 23312702, PMID 24861133, PMID 25697420, PMID 30175268, PMID 30780166, PMID 30936830, PMID 31140114, PMID 32766961, PMID 33412611, PMID 33629819, PMID 35224730, PMID 35574651, PMID 37936786, PMID 38804212, PMID 40682019, PMID 42482263